Recap: Larimar Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Larimar Therapeutics (NASDAQ:LRMR) reported Q4 earnings with an EPS of $-0.3, missing estimates by -20.0%. Revenue remained unchanged from the previous year. The company had previously beaten EPS estimates last quarter, leading to a 14% share price increase the following day.
March 14, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Larimar Therapeutics reported a Q4 EPS of $-0.3, missing estimates by 20%, with unchanged revenue from the previous year.
Missing earnings estimates typically leads to negative investor sentiment and can cause a short-term decline in stock price. The reference to a previous quarter's positive performance following an earnings beat suggests that expectations were likely high, making the miss more impactful.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100